JP4523289B2 - 脳虚血障害又はｃｎｓ障害の処置のための薬剤としてのピペラジンベンゾチアゾール - Google Patents

脳虚血障害又はｃｎｓ障害の処置のための薬剤としてのピペラジンベンゾチアゾール Download PDF

Info

Publication number
JP4523289B2
JP4523289B2 JP2003587807A JP2003587807A JP4523289B2 JP 4523289 B2 JP4523289 B2 JP 4523289B2 JP 2003587807 A JP2003587807 A JP 2003587807A JP 2003587807 A JP2003587807 A JP 2003587807A JP 4523289 B2 JP4523289 B2 JP 4523289B2
Authority
JP
Japan
Prior art keywords
alkyl
substituent
pyrimidin
benzothiazol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003587807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006504631A5 (enExample
JP2006504631A (ja
Inventor
ゲラール，パスカル
ゴットラン，ジャン−ピエール
ビットゥ，ピエール−アラン
Original Assignee
メルク セローノ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク セローノ ソシエテ アノニム filed Critical メルク セローノ ソシエテ アノニム
Publication of JP2006504631A publication Critical patent/JP2006504631A/ja
Publication of JP2006504631A5 publication Critical patent/JP2006504631A5/ja
Application granted granted Critical
Publication of JP4523289B2 publication Critical patent/JP4523289B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003587807A 2002-04-25 2003-04-25 脳虚血障害又はｃｎｓ障害の処置のための薬剤としてのピペラジンベンゾチアゾール Expired - Fee Related JP4523289B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02100417 2002-04-25
PCT/EP2003/004323 WO2003091249A1 (en) 2002-04-25 2003-04-25 Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders

Publications (3)

Publication Number Publication Date
JP2006504631A JP2006504631A (ja) 2006-02-09
JP2006504631A5 JP2006504631A5 (enExample) 2006-06-08
JP4523289B2 true JP4523289B2 (ja) 2010-08-11

Family

ID=29265991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003587807A Expired - Fee Related JP4523289B2 (ja) 2002-04-25 2003-04-25 脳虚血障害又はｃｎｓ障害の処置のための薬剤としてのピペラジンベンゾチアゾール

Country Status (22)

Country Link
US (1) US7314878B2 (enExample)
EP (1) EP1501828B1 (enExample)
JP (1) JP4523289B2 (enExample)
KR (1) KR100948469B1 (enExample)
CN (1) CN1310911C (enExample)
AT (1) ATE383356T1 (enExample)
AU (1) AU2003233067B2 (enExample)
BR (1) BRPI0309594A8 (enExample)
CA (1) CA2481763C (enExample)
CY (1) CY1107204T1 (enExample)
DE (1) DE60318567T2 (enExample)
DK (1) DK1501828T3 (enExample)
EA (1) EA009682B1 (enExample)
ES (1) ES2297165T3 (enExample)
IL (2) IL164796A0 (enExample)
MX (1) MXPA04010474A (enExample)
PT (1) PT1501828E (enExample)
RS (1) RS51407B (enExample)
SI (1) SI1501828T1 (enExample)
UA (1) UA78035C2 (enExample)
WO (1) WO2003091249A1 (enExample)
ZA (1) ZA200408023B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60318567T2 (de) 2002-04-25 2009-02-19 Laboratoires Serono S.A., Coinsins Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns-systems
HRP20070527T3 (en) * 2003-09-12 2007-12-31 Laboratoires Serono Sa Benzothiazole derivatives for the treatment of diabetes
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
JP5144271B2 (ja) * 2004-11-17 2013-02-13 アレス トレーディング ソシエテ アノニム ベンゾチアゾ−ル製剤、及びそれらの使用
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
BRPI0613042A2 (pt) * 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
WO2008125518A2 (en) * 2007-04-17 2008-10-23 Merck Serono S.A. Process for the preparation of piperazine benzothiazoles
KR101368079B1 (ko) * 2008-05-16 2014-03-14 에프. 호프만-라 로슈 아게 Ｊｎｋ 의 억제제
CA2799328C (en) * 2010-06-04 2018-02-20 Humberto Bartolome Arzeno 2 -amino- pyrimidine derivatives useful as inhibitors of jnk
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
WO2014114186A1 (zh) * 2013-01-24 2014-07-31 山东亨利医药科技有限责任公司 Jnk抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4153574B2 (ja) * 1997-09-10 2008-09-24 トーアエイヨー株式会社 新規なピペリジン誘導体、その製造法およびそれを含有する循環器官用剤
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
EP1193256A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
DE60318567T2 (de) 2002-04-25 2009-02-19 Laboratoires Serono S.A., Coinsins Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns-systems

Also Published As

Publication number Publication date
IL164796A (en) 2013-02-28
EP1501828B1 (en) 2008-01-09
US20050261304A1 (en) 2005-11-24
ZA200408023B (en) 2005-11-30
ES2297165T3 (es) 2008-05-01
SI1501828T1 (sl) 2008-04-30
DK1501828T3 (da) 2008-03-10
AU2003233067A1 (en) 2003-11-10
AU2003233067B2 (en) 2009-01-08
DE60318567D1 (de) 2008-02-21
CA2481763A1 (en) 2003-11-06
BRPI0309594A2 (pt) 2016-11-16
EA009682B1 (ru) 2008-02-28
RS92804A (sr) 2006-12-15
EP1501828A1 (en) 2005-02-02
CA2481763C (en) 2011-06-14
PT1501828E (pt) 2008-02-11
MXPA04010474A (es) 2004-12-13
KR100948469B1 (ko) 2010-03-17
EA200401423A1 (ru) 2005-04-28
WO2003091249A1 (en) 2003-11-06
KR20040104572A (ko) 2004-12-10
UA78035C2 (en) 2007-02-15
RS51407B (sr) 2011-02-28
CN1310911C (zh) 2007-04-18
BRPI0309594A8 (pt) 2017-04-11
ATE383356T1 (de) 2008-01-15
CY1107204T1 (el) 2012-11-21
JP2006504631A (ja) 2006-02-09
CN1662528A (zh) 2005-08-31
IL164796A0 (en) 2005-12-18
US7314878B2 (en) 2008-01-01
HK1075664A1 (en) 2005-12-23
DE60318567T2 (de) 2009-02-19

Similar Documents

Publication Publication Date Title
JP5283336B2 (ja) 選択的キナーゼ阻害剤
EP3209656B1 (en) Indole carboxamides compounds useful as kinase inhibitors
BG62089B1 (bg) Инхибитори на hiv реверсивна транскриптаза
US20130196960A1 (en) Cannabinoid Receptor Agonists
EP1569907B1 (en) Nicotinamide-based kinase inhibitors
JP2006504631A (ja) 脳虚血障害又はｃｎｓ障害の処置のための薬剤としてのピペラジンベンゾチアゾール
KR102374033B1 (ko) 특정 단백질 키나제 억제제
KR20070086188A (ko) 키나제 억제제
EP2733144B1 (en) Novel compound having parp inhibitory activity
CN108929312A (zh) 具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
CN106831780A (zh) 具有cdk4/6和hdac抑制活性的新型杂环衍生物
ES2401578T3 (es) Piridinilacetonitrilos
US11905273B2 (en) Inhibitors for the B-catenin/B-cell lymphoma 9 (BCL9) protein-protein interaction
JP5893155B2 (ja) Ｃｒｔｈ２受容体拮抗薬としての窒素含有縮合環式化合物
WO2025122501A1 (en) Benzothiophene-3-yl- and benzoselenophene-3-yl (biclyclic heteroaryl) malemides as gsk-3 inhibitors
HK40083035B (en) Parp7 inhibitor and use thereof
AU2003291839B2 (en) Nicotinamide-based kinase inhibitors
HK40067662A (en) Heterocyclic immunomodulators as pdl1 checkpoint inhibitor
CN113966329A (zh) 作为pdl1检查点抑制剂的杂环免疫调节剂
KR20200078921A (ko) N-아실유레아 유도체를 함유하는 평활근세포 증식, 부착 또는 이동 억제용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060414

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100427

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100527

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4523289

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130604

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees